Liver and thyroid function and autoimmunity during interferon-β1b treatment for MS

Neurology

Volumn 57, Issue 8, 2001, Pages 1363-1370

  Durelli, L ^a,u   Ferrero, B ^a,u   Oggero, A ^a,u   Verdun, E ^a,u   Ghezzi, A ^b,i   Montanari, E ^c,h   Zaffaroni, M ^b,i   Trojano, M ^d   Giuliani, F ^d   Salvi, F ^e   Stecchi, S ^f   Reggio, A ^g   Reggio, E ^g   Negri, G ^h   Ludovico, L ^h   Mancardi, G L ^j   Inglese, M ^j   Carolei, A ^k   Totaro, R ^k   Milanese, C ^l   La Mantia, L ^l   Caputo, D ^m   Mini, M ^m   Mendozzi, L ^m   Cotrufo, R ⁿ   Lus, G ⁿ   Cosi, V ^o   Romani, A ^o   Gallai, V ^p   Sarchielli, P ^p   Nocentini, U ^q   Rizzato, B ^q   Tonali, P A ^r   Massaro, A R ^r   Rosati, G ^s   Sotgiu, S ^s   Annunziata, P ^t   Barbero, P ^u   Isoardo, G L ^u   Pipieri, A ^u   Ricci, A ^u   Cucci, M A ^u   Clerico, M ^u   Bergamaso, B ^u   Aimo, G ^v   Giorda, L ^v   Bortolon, F ^h   Stenta, G ^h   Sormani, M P ^w,x   Beckmann, K ^y   Ecari, U ^z   Ciampini, M ^z   more..

^a UNIVERSITY OF TURIN   (Italy)

^b Ospedale di Gallarate   (Italy)

^c Ospedale di Fidenza   (Italy)

^d Clinica Neurologica   (Italy)

^e BELLARIA HOSPITAL   (Italy)

^f Azienda USL di Bologna   (Italy)

^g Policlinico Universitario   (Italy)

^h Divisione di Neurologia   (Italy)

ⁱ Divisione di Neurologia   (Italy)

^j Clinica Neurologica   (Italy)

^k Clinica Neurologica   (Italy)

^l DEPARTMENT OF NEUROSURGERY   (Italy)

^m Istituto 'Don Gnocchi'   (Italy)

ⁿ Clinica Neurologica   (Italy)

^o Clinica Neurologica   (Italy)

^p Azienda Ospedaliero Universitaria di Perugia   (Italy)

^q UNIVERSITY OF ROME TOR VERGATA   (Italy)

^r CATHOLIC UNIVERSITY   (Italy)

^s Clinica Neurologica dell'Universita   (Italy)

^t Clinica Neurologica   (Italy)

^u Clinica Neurologica   (Italy)

^v MOLINETTE HOSPITAL   (Italy)

^w UNIVERSITY OF GENOA   (Italy)

^x UNIVERSITY OF MILAN   (Italy)

^y BAYER PHARMA AG   (Germany)

^z Angelini SpA   (Italy)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; INTERFERON BETA SERINE; THYROID ANTIBODY; THYROTROPIN;

ADULT; ARTICLE; AUTOIMMUNITY; FEMALE; HUMAN; IMMUNOFLUORESCENCE; IMMUNORADIOMETRIC ASSAY; LIVER FUNCTION; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; RECURRENT DISEASE; THYROID FUNCTION;

EID: 0035940553     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/WNL.57.8.1363     Document Type: Article

References (45)

1. Immunological adverse effects of interferon treatment
2. Immune-mediated side-effects of cytokines in humans
3. Side effects of alpha interferon in chronic hepatitis C
4. Autoimmunity induced by interferon-alpha therapy for chronic viral hepatitis
5. Endocrine and neurological adverse effects of the therapeutic interferons
6. Modulation of the expression of the major histocompatibility antigens
7. Regulation by interferon alpha of immunoglobulin isotype selection and lymphokine production in mice
8. Interferon-gamma-secreting cells in multiple sclerosis patients treated with interferon beta-1b
9. IFN-alpha and IFN-beta. A link between immune memory and chronic inflammation
10. Multiple sclerosis
11. Long term recombinant interferon alpha treatment in MS with special emphasis to side effects
12. Autoimmune hyperthyroidism in patients with multiple sclerosis treated with interferon beta-1b
13. Occurrence of thyroid autoimmunity in relapsing remitting multiple sclerosis patients undergoing interferon-β treatment
14. Occurrence of thyroid autoimmunity and dysfunction throughout a nine-month follow-up in patients undergoing interferon-beta therapy for multiple sclerosis
15. Autoimmune events during interferon beta-lb treatment for multiple sclerosis
16. Long-term interferon beta-1b therapy for MS: Is routine thyroid assessment always useful?
17. Autoimmunity in multiple sclerosis
18. Multiple sclerosis and other immunologic diseases
19. Antithyroid antibodies, in multiple sclerosis
20. Early synthesis and correlation of serum anti-thyroid antibodies with clinical parameters in multiple sclerosis
21. The spectrum of thyroid disease in a community: The Wickham Survey
22. The incidence of thyroid disorders in the community: A twenty year follow-up of the Wickham Survey
23. The epidemiology of thyroid disease and implications for screening
24. Thyroid function and anti-thyroid antibodies in MS patients screened for interferon treatment. A multicenter study
25. An overview of methods for the analysis of longitudinal data
26. New diagnostic criteria for multiple sclerosis: Guidelines for research protocols
27. Screening for thyroid disease: An update
28. American Thyroid Association guidelines for use of laboratory tests in thyroid disorders
29. An autoimmune aetiology for hypothyroidism following interferon therapy for breast cancer
30. Multiple changes in thyroid function in patients with chronic active HCV hepatitis treated with recombinant interferon-alpha
31. Clinical toxicity of the interferons
32. Loss of HBsAg with interferon therapy in chronic hepatitis B virus infection
33. Interferon alpha for patients with clinically apparent cirrhosis due to chronic hepatitis B
34. Interferon beta-lb is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial
35. Randomized double-blind placebo-controlled study of interferon β-1a relapsing/remitting multiple sclerosis
36. Interferon treatment for multiple sclerosis: Autoimmune complications may be lethal
37. Autoantibodies and response to alpha-interferon in patients with chronic viral hepatitis
38. Autoimunity after alpha-interferon therapy for malignant carcinoid tumors
39. Frequency and significance of antinuclear antibodies in multiple sclerosis
40. Antinuclear antibodies and MRI activity in multiple sclerosis
41. Prospective study on thyroid autoimmunity and dysfunction related to chronic hepatitis C and interferon therapy
42. Thyroid autoimmune disorders in patients with chronic hepatitis C before and during interferon-alpha therapy
43. Autoimmunity and thyroid function in patients with chronic active hepatitis treated with recombinant interferon alpha-2a
44. The risk factors for development of thyroid disease during interferon-alpha therapy for chronic hepatitis C